NCT04624633 2026-02-25
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT03283137 2025-02-07
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
University of Chicago
Phase 1 Active not recruiting
NCT04783415 2024-12-02
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting